ABCC12 (MRP9) as a Drug Target and Biomarker: An Overview (G94160)

Target Name: ABCC12

NCBI ID: G94160

ABCC12

ABCC12 (MRP9) as a Drug Target and Biomarker: An Overview

ABCC12 (MRP9) is a member of the ATP-binding cullin (ABCC) family, which is known for its role in intracellular signaling and drug transport. ABCC12 is expressed in various cell types and is involved in the intracellular delivery of various molecules, including small molecules, ions, and proteins. The ABCC12 protein has been shown to play a critical role in the regulation of mitochondrial function, and its dysfunction has been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

Drugs that target ABCC12 have the potential to treat various diseases. For example, inhibitors of ABCC12 have been shown to be effective in treating neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, ABCC12 has been shown to be involved in cancer cell signaling, which has led to the development of inhibitors of ABCC12 as potential cancer treatments.

Importance of ABCC12 as a Drug Target

ABCC12 plays a critical role in the regulation of mitochondrial function and has been shown to play a role in the development and progression of various diseases. Its dysfunction has been implicated in the development of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. ABCC12 has also been shown to be involved in cancer cell signaling, which has led to the development of inhibitors of ABCC12 as potential cancer treatments.

ABCC12 is a transmembrane protein that is expressed in various cell types, including neurons, macrophages, and cancer cells. It is involved in the regulation of mitochondrial function, including the transport of various molecules, including small molecules, ions, and proteins. ABCC12 has been shown to play a critical role in the regulation of mitochondrial function and metabolism, which are essential for the survival and growth of cells.

In neurodegenerative diseases, ABCC12 dysfunction has been implicated in the development and progression of the diseases. For example, studies have shown that ABCC12 dysfunction is associated with the development of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, ABCC12 has been shown to be involved in the production of reactive oxygen species (ROS), which can damage cellular components and contribute to the development of neurodegenerative diseases.

In cancer, ABCC12 has been shown to play a role in cancer cell signaling. ABCC12 has been shown to be involved in the production of various signaling molecules, including TGF-β, NF-kappa-B, and PI3K. Additionally, ABCC12 has been shown to play a critical role in the regulation of mitochondrial function, which is essential for the growth and survival of cancer cells.

In conclusion, ABCC12 is a drug target with potential in treating neurodegenerative diseases and cancer. The development of inhibitors of ABCC12 has the potential to provide new treatments for these diseases. Further research is needed to fully understand the role of ABCC12 in disease and to develop effective treatments.

Protein Name: ATP Binding Cassette Subfamily C Member 12

Functions: Probable transporter, its substrate specificity is unknown

The "ABCC12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABCC12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets